We are live on ! Find out more
GBIO

Generation Bio

Delisted

GBIO was delisted on the 6th of February, 2026.

48 hedge funds and large institutions have $24.5M invested in Generation Bio in 2025 Q4 according to their latest regulatory filings, with 11 funds opening new positions, 10 increasing their positions, 15 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

175% more first-time investments, than exits

New positions opened: 11 | Existing positions closed: 4

100% more funds holding in top 10

Funds holding in top 10: 12 (+1)

17% more funds holding

Funds holding: 4148 (+7)

5.07% more ownership

Funds ownership: 58.93%64% (+5.1%)

1% more capital invested

Capital invested by funds: $24.2M → $24.5M (+$283K)

33% less repeat investments, than reductions

Existing positions increased: 10 | Existing positions reduced: 15

Holders
48
Holders Change
+7
Holders Change %
+17.07%
% of All Funds
0.58%
Holding in Top 10
2
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+100%
% of All Funds
0.02%
New
11
Increased
10
Reduced
15
Closed
4
Calls
Puts
Net Calls
Net Calls Change
Name Holding Trade Value Shares
Change
Change in
Stake
Carson Wealth (CWM LLC)
51
Carson Wealth (CWM LLC)
Nebraska
-$40 -7 -88%

GBIO Hedge Fund Activity: Q4 2025 in Review

48 of the 8,243 institutional investors tracked by Wall St. Rank reported a position in Generation Bio (GBIO) for Q4 2025, worth a combined $24.5M — up 1.2% from $24.2M a quarter earlier.

Buyers outnumbered sellers: 11 funds opened new GBIO positions and 4 closed out — a net gain of 7 holders — while 10 added to existing stakes and 15 trimmed.

The largest buyer was Opaleye Management, opening a new position worth an estimated $1.75M. The largest seller was T. Rowe Price Associates, cutting an estimated $2.07M.

  • 48 institutional investors held Generation Bio (GBIO) as of Q4 2025, up from 41 in Q3 2025.
  • Funds reported $24.5M of Generation Bio stock for Q4 2025, up 1.2% quarter-over-quarter.
  • 11 funds opened new Generation Bio positions in Q4 2025 and 4 closed out, a net change of +7 holders.
  • The largest Generation Bio buyer in Q4 2025 was Opaleye Management, an estimated $1.75M added.
  • The largest Generation Bio seller in Q4 2025 was T. Rowe Price Associates, an estimated $2.07M sold.

Based on aggregated 13F filings for Q4 2025.